Crizotinib in Patients With MET-Amplified NSCLCD. Ross Camidge, Liza C. Villaruz, Jared Weiss et al.|Journal of Thoracic Oncology|2021Cited by 171
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.D. Ross Camidge, Liza C. Villaruz, Gregory A. Otterson et al.|Journal of Clinical Oncology|2018Cited by 80